Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial.
Kathryn CardozaAmy KangBrendan SmythTae Won YiCarol PollockRajiv AgarwalGeorge BakrisDavid M CharytanDick de ZeeuwDavid C WheelerHong ZhangChristopher P CannonVlado PerkovicClare ArnottAdeera LevinKenneth W MahaffeyPublished in: Diabetes, obesity & metabolism (2024)
Canagliflozin reduces the risk of kidney and cardiovascular events similarly across geographic regions and racial groups.